Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
NCT ID: NCT06427304
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
637 participants
OBSERVATIONAL
2024-07-01
2028-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis
NCT04636684
Registry of Patients with Suspected Amyloidosis in Heart Failure
NCT05176548
Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
NCT00456040
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
NCT02798705
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.
NCT02260466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be recruited for 24 months. Each patient will participate in the study for 12 months (baseline visit, follow-up phone calls every 3 months up to 12 months i.e., at 3, 6, 9 and 12 months).
The following data will be collected at teh baseline visit: Medical history, demography, clinical data, frailty status assessed by Fried, Triage Risk Screening Tool (TRST), triggers for cardiac decompensation, biological examination, genetic testing, echocardiographic data and other data.
Bone scanning with 99mTc-DPD or 99mTc-HMDP (early or late time with SPECT will be done during hospitalization or after discharge depending on availability at the imaging centre.
The results of each examination will be evaluated to establish the existence and degree of fixation in the myocardium and to determine its distribution.
Follow-up phone s will be conducted every 3 months up to 12 months to collect hospitalizations for heart failure, hospitalizations for other cardio-vascular events, hospitalizations for non-cardiac events, admission to nursing homes or long-term care (LTC) facilities and death
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalised for decompensation of heart failure in the last 12 months
* Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm)
* Subjects able to undergo a bone scintigraphy scan
* Subjects willing to participate
Exclusion Criteria
* Subjects admitted to palliative care unit.
* Subjects under guardianship
* Subjects with a definite diagnosis of cardiac amyloidosis
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gérond'if
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier Hanon, MD PhD
Role: STUDY_CHAIR
Geriatric Department, Broca hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geriatric Department, Broca Hospital
Paris, IIe-de-France, France
CHU Nantes
Nantes, Loire-Atlantique, France
CHU Rouen, Charles Nicole hospital
Rouen, Normandy, France
CHU Poitiers
Poitiers, Nouvelle-Aquitaine, France
CHU Montpellier
Montpellier, Occitanie, France
CHU Toulouse
Toulouse, Occitanie, France
CHU Amiens Picardie
Amiens, , France
CHU Angers
Angers, , France
CHU Bordeaux
Bordeaux, , France
Centre Hospitalier de Carcassonne
Carcassonne, , France
Centre Hospitalier Intercommunal de Castres-Mazamet
Castres, , France
CHU Trousseau-Tours
Chambray-lès-Tours, , France
CHU Dijon
Dijon, , France
CHU Grenoble Alpes
Grenoble, , France
CHU Lille
Lille, , France
CHU Limoges
Limoges, , France
CHU Lyon
Lyon, , France
CHU Marseille
Marseille, , France
Clinique du Millénaire-Montpellier
Montpellier, , France
CHRU Nancy
Nancy, , France
CHU Nice
Nice, , France
Hôpital Privé Gériatrique LES SOURCES-Nice
Nice, , France
CHU Orléans
Orléans, , France
CHU Rennes
Rennes, , France
CHRU Tours-Bretonneau Hospital
Tours, , France
Clinique Saint Joseph Trelaze
Trélazé, , France
Médipôle Hôpital Mutualiste Villeurbanne
Villeurbanne, , France
Ambroise Paré Hospital
Boulogne-Billancourt, Île-de-France Region, France
Corentin Celton Hospital
Issy-les-Moulineaux, Île-de-France Region, France
Charles Foix Hospital
Ivry-sur-Seine, Île-de-France Region, France
Emile Roux Hospital
Limeil-Brévannes, Île-de-France Region, France
GH Sud Ile-de-France
Melun, Île-de-France Region, France
Lariboisière Hospital
Paris, Île-de-France Region, France
Saint Joseph Hospital
Paris, Île-de-France Region, France
Europeen Georges Pompidou Hospital
Paris, Île-de-France Region, France
Bretonneau Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne Sophie BOUREAU, MD
Role: primary
Frédéric ROCA, MD
Role: primary
Marc PACCALIN, MD, PHD
Role: primary
Hubert BLAIN, MD, PHD
Role: primary
Olivier TOULZA, MD
Role: primary
Nysrine BENNOUNA, MD
Role: primary
Cédric NNWEILER, MD, PHD
Role: primary
Isabelle BOURDEL-MARCHASSON, MD, PHD
Role: primary
Hanna BAKANOVA, Dr
Role: primary
Soumiya MENHOUR, MD
Role: primary
Laurent FAUCHIER, MD, PHD
Role: primary
Jérémie VOVELLE, MD
Role: primary
Laure ALLAN-PATTOGLIA, MD
Role: primary
François PUISIEUX, MD, PHD
Role: primary
Achille TCHALLA, MD
Role: primary
Michel CHUZEVILLE, MD
Role: primary
Anne-Laure COUDERC, MD, PHD
Role: primary
Philippe GALLET DE SANTERRE, Dr
Role: primary
Laure JOLY, MD
Role: primary
Olivier GUERIN, MD, PHD
Role: primary
Anne-Marie BARISIC, MD
Role: primary
Matthieu COULONGEAT, MD
Role: primary
Dominique SOMME, MD, PHD
Role: primary
Erwan DONAL, MD, PhD
Role: backup
Bertrand FOUGERE, MD, PHD
Role: primary
Laureen LABORY, MD
Role: primary
Antoine JOBBE-DUVAL, MD
Role: primary
Marion PEPIN, MD
Role: primary
Anthony MEZIERE, MD
Role: primary
Joël BELMIN, MD, PHD
Role: primary
Amaury BROUSSIER, MD
Role: primary
Cyrus MOÏNI, MD
Role: primary
Matthieu LILAMAND, MD
Role: primary
Yara ANTAKLY HANON, MD
Role: primary
Elena PAILLAUD, MD, PHD
Role: primary
Virginie FOSSEY-DIAZ, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01313-42
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.